Jarrod Longcor
Chief Operating Officer Cellectar Biosciences
Wednesday 16th September 2026
Roundtable Discussion: Future-Proofing Isotope Supply by Diversifying Global Sourcing Strategies to Mitigate Risk & Ensure Continuity
11:30 am
- Evaluating current and emerging isotope supply landscapes across alpha and beta emitters
- Comparing production routes (reactor, cyclotron, generator-based) and understanding implications for scalability and reliability
- Designing multi-supplier models (primary, secondary, tertiary) to safeguard continuity of clinical supply
Thursday 17th September 2026
Panel Discussion: Future Directions – Where Does the Chain Break? A Collective Assessment of the Industry’s Most Critical Unresolved Supply Chain Challenges & the Priorities That Must Be Addressed Collectively Before the Next Wave of Approvals Arrives
4:00 pm
- Across the two days, which single supply chain or manufacturing bottleneck has emerged as most urgent, and what does a credible industry-level response to it look like?
- Where does the field realistically stand on isotope supply security in five years, and which production pathways, technologies, and investment models will determine whether commercial-scale alpha therapy becomes a reality?
- How must the relationship between biopharma, CDMOs, isotope providers, logistics specialists, and clinical sites evolve structurally to one that can reliably deliver therapies to patients at scale?
Wednesday 16th September 2026
Chair’s Opening Remarks
9:05 am
